Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
+6
Published on July 3
These companies are developing therapies that could transform survival rates for blood cancer patients. Recent FDA approvals validate both the technology and massive market potential.
Advanced cancer treatments command high prices due to their life-extending benefits. Companies with approved therapies for late-stage cancers can generate substantial revenue even with relatively small patient populations.
This group includes pioneers in immunotherapy technologies that go beyond traditional treatments. Their innovations could potentially expand to other cancer types, multiplying their market opportunities.
The FDA's approval of new bispecific antibodies for multiple myeloma has created a watershed moment for cancer treatment innovation. This validation opens doors for companies developing similar groundbreaking therapies that can command premium pricing while addressing critical patient needs.
This collection includes research-intensive biopharmaceutical companies focused on next-generation cancer treatments. These stocks represent a growth-oriented investment in biotechnology innovation, with companies ranging from established pharmaceutical giants to specialized biotech firms.
Each company was selected based on their direct involvement in developing advanced treatments for multiple myeloma. They're either pioneers who've received recent approvals, direct competitors with similar technologies, or key enablers of bispecific antibody and CAR-T therapies.
Market capitalisation breakdown for the Next-Gen Multiple Myeloma Treatments basket.
REGN: $61.40B
JNJ: $462.30B
PFE: $141.29B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Johnson & Johnson
JNJ
Current Price
$273.23
A direct competitor with two approved multiple myeloma treatments: Tecvayli, a BCMA-targeted bispecific antibody, and Carvykti, a leading CAR-T therap...
A direct competitor with two approved multiple myeloma treatments: Tecvayli, a BCMA-targeted bispecific antibody, and Carvykti, a leading CAR-T therapy.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+68.97%
On average, analysts expect assets in this group to grow 68.97% over the next year.
13 of 16 assets in this group are rated Buy by professional analysts.
